On the antitumor properties of novel cyclometalated benzimidazole Ru(ii), Ir(iii) and Rh(iii) complexes

Yellol, Gorakh S.; Donaire, Antonio; Yellol, Jyoti G.; Vasylyeva, Vera; Janiak, Christoph; Ruiz, José

doi:10.1039/c3cc46239k

Cited by 107 publications

(79 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14), and these complexes were efficacious in HT29, T47D, A2780 and A2780cisR cancer cell lines. 163 The IC 50 value of 8a , a representative compound, was 2.18 μM in HT29 cancer cells, indicating that it is more efficacious than cisplatin (IC 50 : 9 μM). Further studies indicated that 8a induces a high rate of apoptosis, good accumulation, S-phase cell cycle arrest, strong binding to HSA at sites I and II, and weak binding to DNA in the minor groove.…”

Section: Arene Ruthenium(ii) Complexesmentioning

confidence: 99%

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

et al. 2017

View full text Add to dashboard Cite

Cancer is rapidly becoming the top killer in the world. Most of the FDA approved anticancer drugs are organic molecules, while metallodrugs are very scarce. The advent of first metal based therapeutic agent, cisplatin, launched a new era in the application of transition metal complexes for therapeutic design. Due to their unique and versatile biochemical properties, ruthenium-based compounds have emerged as promising anti-cancer agents that serve as alternatives to cisplatin and its derivertives. The ruthenium(III) complexes have successfully been used in clinical research and their mechanisms of anticancer action have been reported in large volumes over the past few decades. Ruthenium(II) complexes have also attracted significant attention as anticancer candidates; however, only few of them have been reported comprehensively. In this review, we discuss the development of ruthenium(II) complexes as anticancer candidates and biocatalysts, including arene ruthenium complexes, polypyridyl ruthenium complexes, and ruthenium nanomaterial complexes. This review focuses on the likely mechanisms of action of ruthenium(II)-based anticancer drugs and the relationship between their chemical structures and biological properties. This review also highlights the catalytic activity and the photoinduced activation of ruthenium(II) complexes, their targeted delivery, and their activity in nanomaterial systems.

show abstract

Section: Arene Ruthenium(ii) Complexesmentioning

confidence: 99%

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

et al. 2017

View full text Add to dashboard Cite

show abstract

“…98,101 Reports by Novohradsky et al showed that the neutral N,N-compound 22 are inactive (IC 50 > 100¯M) against ovarian and breast carcinomas, whereas the cationic C,N-compound 23 exhibited potency similar to CDDP against the ovarian cell lines, A2780 and A2780cis. 106 Upon assessing the cellular accumulation, it was noted that energy-passive diffusion plays a significant role, and the amount of uptake was enhanced by the depletion of intracellular ATP.…”

Section: Iridium(iii) Compoundsmentioning

confidence: 99%

Organometallic Iridium Arene Compounds: The Effects ofC-Donor Ligands on Anticancer Activity

Lord

McGowan

2019

Chem. Lett.

View full text Add to dashboard Cite

Rianne M. Lord obtained her Ph.D. degree in chemistry in 2014 under the supervision of Professor Patrick C. McGowan at the University of Leeds (U.K.). Following this, she joined the research team of Professor Polly L. Arnold at the University of Edinburgh (U.K.) as a postdoctoral research associate. In 2016, Rianne began her independent career as a lecturer of bioinorganic chemistry at the University of Bradford (U.K.) and currently holds an August-Wilhelm Scheer visiting professorship at the Technische Universität München (Germany). Her research interests focus on the development of new transition metal cancer therapeutics and designing effective drug delivery systems.

show abstract

“…Ir, Rh, Ru and Os, have shown great potential for biological targets. [4][5][6][7][8] Meanwhile, Ir(III) complexes have found important applications in elds of research ranging from materials to catalysis based on their interesting photo-physical and photo-chemical properties. 9 They are known to be efficient phosphors in OLEDs or imaging agent and sensors.…”

Section: Introductionmentioning

confidence: 99%

Experimental and theoretical investigation of cyclometalated phenylpyridine iridium(iii) complex based on flavonol and ibuprofen ligands as potent antioxidant

2019

View full text Add to dashboard Cite

show abstract

On the antitumor properties of novel cyclometalated benzimidazole Ru(ii), Ir(iii) and Rh(iii) complexes

Cited by 107 publications

References 20 publications

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

Organometallic Iridium Arene Compounds: The Effects ofC-Donor Ligands on Anticancer Activity

Experimental and theoretical investigation of cyclometalated phenylpyridine iridium(iii) complex based on flavonol and ibuprofen ligands as potent antioxidant

Contact Info

Product

Resources

About